Sip Wijchers: Is It Time to Use Ultrasound for Every AF Ablation Access?
Sip Wijchers, Cardiologist-electrophysiologist at Erasmus MC, shared a post on LinkedIn:
”We’ve optimized anticoagulation in AF ablation. But what about the puncture?
Vascular access complications remain the most common adverse event in AF ablation. And yet, many labs still rely on landmark-based femoral venous access.
The ULYSSES trial challenges that habit.
In 986 patients undergoing AF/LA tachycardia ablation, ultrasound-guided access reduced clinically relevant vascular complications from 3.3% to 0.6% (RR 0.19, p=0.002) (Schaack et al., 2026).
But the real signal may be elsewhere:
- Arterial puncture: 16% – 2%
- Failed venous access: 8.2% – 0.2%
- No increase in procedure time
This is not about marginal gains.
This is about predictability and safety at the very first step of the procedure.
And importantly, this aligns with decades of data across vascular access:
Ultrasound improves success and reduces complications in central lines, subclavian access, and femoral arterial puncture (Teja et al., 2024; Zawadka et al., 2023; Strauss et al., 2025).
So the real question is no longer does it help?
It’s:
Can we still justify not using it?
- Yes, the absolute risk reduction is modest.
- Yes, the trial was stopped early.
But when a low-cost, widely available tool reduces the most frequent complication of a high-volume procedure… the bar for “routine use” should be low.
Should ultrasound-guided femoral venous access now be the default in AF ablation?
Or is palpation still acceptable in experienced hands?
Curious how this is implemented in your lab.”

Stay updated with Hemostasis Today.
-
May 6, 2026, 18:03Shiv Choudhary: Did You Know That Varicose Veins Can Be Detected with a Simple Test?
-
May 6, 2026, 17:48A Hidden Mechanical Cause of Recurrent Thrombosis in a Young Athlete – The Lancet
-
May 6, 2026, 17:26Joanna Fraser: Highlights from WFH Congress 2026 in Malaysia
-
May 6, 2026, 17:04Nour Al-Mozain: Massive Transfusion in Pediatrics
-
May 6, 2026, 16:36Ney Carter Borges: Randomized Trial of the Vascular Effects of Low-Dose Colchicine in High-Risk Type 2 Diabetes
-
May 6, 2026, 16:35Giuseppe Lippi: Essential Laboratory Testing in Emergencies
-
May 6, 2026, 16:28Anna-Maria Tsilia: Addressing Psychological Aspects of Hemophilia at WFH 2026
-
May 6, 2026, 16:25Manuel A. Lopez Serrano: Mastering Healthcare Through Family, Faith, and Hemophilia
-
May 6, 2026, 16:24Elena Donoso Úbeda: Attending WFH 2026 for Manual Therapy Workshop and Global Collaboration